Adverse effects of SGLT2 inhibitors on bone health

Nature Reviews Nephrology

Volumn 14, Issue 8, 2018, Pages 473-474

  Blau, Jenny E ^a   Taylor, Simeon I ^a,b  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; FIBROBLAST GROWTH FACTOR 23; PHOSPHATE; PLACEBO; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; 1,25-DIHYDROXYVITAMIN D; FIBROBLAST GROWTH FACTOR; PARATHYROID HORMONE; PHOSPHORUS; VITAMIN D;

ACUTE KIDNEY FAILURE; BODY WEIGHT LOSS; BONE DENSITY; CHRONIC KIDNEY FAILURE; CORRELATION ANALYSIS; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; FRACTURE; HOSPITALIZATION; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; ORTHOSTATIC HYPOTENSION; OSTEOLYSIS; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; REVIEW; RISK ASSESSMENT; ANALOGS AND DERIVATIVES; BLOOD; BONE DEMINERALIZATION; CHEMICALLY INDUCED; DRUG EFFECT; DRUG THERAPY;

BONE DEMINERALIZATION, PATHOLOGIC; BONE DENSITY; CANAGLIFLOZIN; FIBROBLAST GROWTH FACTORS; FRACTURES, BONE; HUMANS; PARATHYROID HORMONE; PHOSPHORUS; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; VITAMIN D;

EID: 85048129838     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/s41581-018-0028-0     Document Type: Review

References (6)

1. DeFronzo, R. A., Norton, L. &Abdul-Ghani, M. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat. Rev. Nephrol. 13, 11-26 (2017).
2. Kohan, D. E., Fioretto, P., Tang, W. &List, J. F. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 85, 962-971 (2014).
3. Bilezikian, J. P. et al. Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes treated with canagliflozin. J. Clin. Endocrinol. Metab. 101, 44-51 (2016).
4. Watts, N. B. et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 101, 157-166 (2016).
5. Blau, J. E. et al. Canagliflozin triggers the FGF23/1,25-dihydroxyvitamin D/PTH axis in healthy volunteers in a randomized crossover study. JCI Insight 3, 99123 (2018).
6. Pitts, R. F. &Alexander, R. S. The renal reabsorptive mechanism for inorganic phosphate in normal and acidotic dogs. Am. J. Physiol. 142, 648-662 (1944).